Shattuck Labs’ (STTK) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Shattuck Labs (NASDAQ:STTK) in a report published on Friday morning, Benzinga reports. They currently have a $16.00 target price on the stock.

Other analysts have also recently issued research reports about the stock. BTIG Research cut shares of Shattuck Labs from a buy rating to a neutral rating in a research note on Monday, June 17th. Needham & Company LLC reduced their price target on Shattuck Labs from $12.00 to $8.00 and set a buy rating for the company in a report on Friday, June 14th. Finally, Citigroup cut their price objective on Shattuck Labs from $10.00 to $9.00 and set a buy rating for the company in a research report on Monday, June 17th.

Shattuck Labs Price Performance

Shares of NASDAQ STTK opened at $3.06 on Friday. The business has a 50-day moving average of $4.93 and a 200-day moving average of $7.76. The stock has a market capitalization of $145.50 million, a price-to-earnings ratio of -1.59 and a beta of 1.73. Shattuck Labs has a fifty-two week low of $1.33 and a fifty-two week high of $11.76.

Shattuck Labs (NASDAQ:STTK) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.01). The company had revenue of $1.61 million for the quarter, compared to analyst estimates of $0.50 million. Shattuck Labs had a negative return on equity of 66.23% and a negative net margin of 2,067.99%. The firm’s revenue for the quarter was up 704.5% on a year-over-year basis. On average, sell-side analysts expect that Shattuck Labs will post -1.56 EPS for the current year.

Insider Buying and Selling at Shattuck Labs

In other Shattuck Labs news, CEO Taylor Schreiber acquired 14,400 shares of the business’s stock in a transaction on Wednesday, June 26th. The stock was purchased at an average price of $3.47 per share, with a total value of $49,968.00. Following the acquisition, the chief executive officer now directly owns 34,502 shares of the company’s stock, valued at approximately $119,721.94. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On Shattuck Labs

Institutional investors and hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC bought a new stake in shares of Shattuck Labs during the 4th quarter worth approximately $268,000. Reliant Investment Management LLC acquired a new stake in shares of Shattuck Labs in the 4th quarter valued at $143,000. Franklin Resources Inc. bought a new position in shares of Shattuck Labs in the 4th quarter valued at $11,663,000. Monashee Investment Management LLC acquired a new position in shares of Shattuck Labs during the 4th quarter worth $713,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of Shattuck Labs by 79.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 13,553 shares of the company’s stock worth $97,000 after buying an additional 5,989 shares during the last quarter. Institutional investors own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.